Form 4: Citius Oncology Director Boosts Equity Holdings

Citius Oncology Director Carol Webb reports acquisition of 300,000 restricted common shares and details existing stock options.

Summary

• Carol Webb, a Director of Citius Oncology, Inc. (CTOR), reported changes in her beneficial ownership.
• On September 19, 2025, Ms. Webb was granted 300,000 restricted shares of common stock at a price of $0.
• These restricted shares will vest in three substantially equal annual installments on the first, second, and third anniversaries of the grant date, contingent on her continuous service to the company.
• Ms. Webb also holds 125,000 stock options with an exercise price of $1.07, granted on December 12, 2024, which will vest 1/3 on each of the one-year, two-year, and three-year anniversaries of the grant date, subject to continuous service.
• Additionally, she holds 150,000 fully vested stock options with an exercise price of $2.15, which expire on July 5, 2033.
• Following these transactions, Ms. Webb directly beneficially owns 300,000 common shares and 275,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates a significant equity grant to a director, aligning her interests with shareholders and suggesting long-term commitment, which is generally viewed positively for corporate governance and stability.

Positives

• Director Carol Webb received a grant of 300,000 restricted common shares, aligning her interests with long-term shareholder value.
• The vesting schedule for both the restricted stock and a portion of the stock options incentivizes Ms. Webb's continuous service and commitment to the company's performance over several years.

Risks

• The value of the restricted stock and stock options is subject to the future performance and market price fluctuations of Citius Oncology's common stock.
• Vesting of the restricted stock and a portion of the stock options is contingent upon Ms. Webb's continuous service to the company or a related entity.

Future Outlook

The vesting schedules for the 300,000 restricted shares (over three years) and 125,000 stock options (over three years) indicate a long-term incentive structure designed to retain Director Carol Webb and align her interests with the company's sustained performance.

Industry Context

Equity grants, such as restricted stock and stock options, are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term shareholder value creation, particularly in companies like Citius Oncology that may have significant future growth potential tied to drug development.

Stakeholder Impact

• Shareholders: The equity grants to a director align management's interests with shareholder value creation, potentially fostering long-term commitment and performance.
• Employees: The continuous service requirement for vesting may signal stability in leadership and a commitment to long-term strategic goals.

Next Steps

• Vesting of 300,000 restricted shares in three equal annual installments starting September 19, 2026.
• Vesting of 125,000 stock options in three equal annual installments starting December 12, 2025.

Key Dates

Keywords

Citius Oncology, CTOR, Form 4, Beneficial Ownership, Insider Transaction, Restricted Stock, Stock Options, Director Compensation, Equity Grant